AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to AstraZeneca
Related studies linked through entity extraction aliases.
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
- Status
- COMPLETED
- Phase
- PHASE1
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
- Status
- COMPLETED
- Phase
- N/A
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Status
- RECRUITING
- Phase
- PHASE3
HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council
- Status
- COMPLETED
- Phase
- N/A
Non-alcoholic Steatohepatitis Registry Platform Study
- Status
- TERMINATED
- Phase
- N/A
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
- Status
- WITHDRAWN
- Phase
- PHASE2
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Chronic Kidney Disease Registry Platform Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3